Amyndas Pharmaceuticals
  • Home
  • About
    • What We Do
    • Founder’s Bio
    • Management
  • Research & Development
    • Our Focus
    • Our Pipeline
    • Clinical Trials
    • Technology
    • Selected Publications
    • Notes on Targeted Conditions
  • News
  • Contact Us
  • LinkedIn
  • Twitter
  • Home
  • About
    • What We Do
    • Founder’s Bio
    • Management
  • Research & Development
    • Our Focus
    • Our Pipeline
    • Clinical Trials
    • Technology
    • Selected Publications
    • Notes on Targeted Conditions
  • News
  • Contact Us
  • LinkedIn
  • Twitter

Forsyth Dentech 2021: Presentation by Amyndas’ Managing Director Dr. Yancopoulou

on October 11, 2021

Dr. Despina Yancopoulou, the Managing Director of Amyndas Pharmaceuticals, presented Amyndas’ promising new treatment for periodontal inflammation at Forsyth Dentech 2021.

To view presentation, click here.

Latest News

  • EUSTM (9th Congress): Novel Transformative Treatment for Periodontal Disease

  • Complement C3 inhibition in severe COVID-19 using compstatin AMY-101

  • Review: Compstatins: the dawn of clinical C3-targeted complement inhibition

  • JCI Video: Complement C3 Inhibitor AMY-101 in Adults with Periodontal Inflammation – Clinical Trial

 

Latest Publications

  • Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis

  • Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy

  • The first case of COVID-19 treated with the complement C3 inhibitor AMY-101

  • Complement as a target in COVID-19?

 
 

Copyright © 2022 Amyndas Pharmaceuticals. All Rights Reserved.